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Abstract
Background: The contributions of vascular risk factors to spinocerebellar ataxia (SCA) are not known.
Methods: We studied 319 participants with SCA 1, 2, 3, and 6 and repeatedly measured clinical severity using the Scale for Assessment and Rating of Ataxia
(SARA) for 2 years. Vascular risk factors were summarized by CHA2DS2-VASc scores as the vascular risk factor index. We employed regression models to study the
effects of vascular risk factors on ataxia onset and progression after adjusting for age, sex, and pathological CAG repeats. Our secondary analyses took
hyperlipidemia into account.
Results: Nearly 60% of SCA participants were at low vascular risks with CHA2DS2-VASc50, and 31% scored 2 or greater. Higher CHA2DS2-VASc scores were
not associated with either earlier onset or faster progression of ataxia. These findings were not altered after accounting for hyperlipidemia.
Discussion: Vascular risks are not common in SCAs and are not associated with earlier onset or faster ataxia progression.
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Introduction
CAG repeat disorders are a group of neurodegenerative diseases,
including Huntington’s disease (HD), dentatorubral-pallidoluysian
atrophy, and spinocerebellar ataxia (SCA) types 1, 2, 3, 6, 7, and
17, and others. These diseases are inherited in an autosomal dominant
fashion and neuropathological findings usually reveal neuronal
inclusions of polyglutamine aggregates.1 The age of onset and disease
progression in ataxia are inversely associated with the number of
pathological CAG repeats.2,3 Polyglutamine repeat expansions cause
defective protein quality control and mitochondrial dysfunction
leading to neuronal death.4 The pathological CAG repeats, however,
explain only 50–70% of the variability of the age of disease onset in
CAG repeat-related SCAs, suggesting the existence of disease
modifiers other than CAG repeats.5–8
Cerebrovascular disease, atherosclerosis, hypertension, diabetes
mellitus, and hyperlipidemia, are associated with vascular dementia
and Alzheimer’s disease (AD).9 Vascular pathology is often seen in
elderly patients with various types of dementia. The concept of
neurovascular units has been proposed to explain the vascular
contributions to neurodegeneration; blood–brain barrier breakdown,
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hypoperfusion, and endothelial dysfunction likely lead to neuronal
dysfunction.10 The neurovascular change may have well elucidated the
disordered amyloid metabolism in AD and the mixture of vascular and
AD pathologies commonly seen in dementia.
Vascular risk factors have also been studied in Parkinson’s disease
(PD). Hypertension and diabetes do not seem to directly contribute to
the risk of PD, whereas increased blood cholesterol levels are
associated with a higher risk of PD.11 Interestingly, statin use is
associated with a lower risk of PD12 and discontinuation of statin use
has an opposite effect.13 Vascular risk factors and cerebral white
matter hyperintensity are associated with mild cognitive impairment in
PD.14 In amyotrophic lateral sclerosis, hyperlipidemia is a good
prognostic factor.15 Microvascular abnormality has been identified in
post-mortem HD brains16 and the presence of additional vascular
insults could further influence the disease progression. Despite the
extensive interest in vascular risk factors in neurodegenerative diseases,
the concept has not yet been successfully applied to SCAs.
Anatomically, the cerebellum and brainstem are two heavily
involved regions in SCA1, 2, and 3 whereas the pathology of SCA6
is relatively restricted to the cerebellum.17 These brain regions are
prone to vascular insults as ataxia-hemiparesis and dysarthria-clumsy
hand are classical symptoms for lacunar infarcts. Interestingly,
increased white matter vascular burden in the cerebellum has been
observed in another cerebellar disorder, essential tremor.18 These
findings emphasize the potential role of vascular risk factors in
cerebellar ataxia disorders.
We herein tested the hypothesis of neurovascular concept outside
the dementia context by studying the role of vascular risk factors in
disease onset and progression in SCA types 1, 2, 3, and 6 from the
Clinical Research Consortium-Spinocerebellar Ataxia (CRC-SCA).
Methods
Study subjects
Three hundred and nineteen study participants were recruited by
ataxia or movement disorders specialists during July 2009 to May 2012
from 12 CRC-SCA centers. The uniform study protocol was approved
by the local institutional review boards and informed consents were
obtained from all participants. Our inclusion criteria were 1) the
presence of ataxia, 2) definite genetic diagnosis of SCA1, 2, 3, or 6,
either for the subject or for another affected family member with
ataxia, 3) willingness to participate, and 4) age 6 years and older. The
exclusion criteria were 1) known recessive, X-linked, and mitochon-
drial ataxias, 2) exclusion of SCA1, 2, 3, and 6 by previous genetic
tests, 3) concomitant disorder(s) that affect the Scale for Assessment
and Rating of Ataxia (SARA) and other ataxia measurements used in
this study. Basic demographics were recorded and all participants were
asked to provide blood samples for SCA genotyping. Study
participants were followed every 6 months till 2 years from the
baseline visit or the end of August 2012, when the study was closed. In
each visit, the severity of ataxia was recorded by a trained ataxia expert
using SARA scores, which measure eight different domains of ataxia
symptoms.19 Comorbid medical conditions such as hypertension,
diabetes mellitus, congestive heart failure, and hyperlipidemia were
collected.
Genetic testing
DNA samples from blood of 263 participants were obtained and
CAG repeat expansions were determined in S.M.P.’s laboratory.3
Blood samples of thirty-seven patients were not available in the
research laboratory; we used repeat numbers from commercial
laboratories. In 19 patients, the information of CAG repeat
expansions was not available (one SCA1, five SCA2, 10 SCA3, three
SCA6).
Predictor variables
CHA2DS2-VASc (clinical predictive score based on congestive heart
failure, hypertension, age >75, diabetes, prior stroke, vascular disease,
age 65–74, sex category) is a scoring system for predicting the risk of
stroke in patients with non-rheumatic atrial fibrillation (range: 0–9).
The CHA2DS2-VASc score is primarily used to determine whether
anticoagulant treatment is required and has also been employed to
predict stroke risks in patients without atrial fibrillation.20 CHA2DS2-
VASc scores are calculated based on age, sex, history of congestive
heart failure, hypertension, stroke or transient ischemic attacks or
thromboembolism, vascular disease (peripheral artery disease, myo-
cardial infarction, aortic plaques), and diabetes mellitus.21 Higher
scores indicate higher risks of developing a cerebrovascular event.
Hyperlipidemia is a major cardiovascular risk but not included in the
original version of the CHA2DS2-VASc score; thus we took
hyperlipidemia into account and developed modified CHA2DS2-
VASc scores. We used modified CHA2DS2-VASc scores to reflect
vascular risk factors or cerebrovascular health.
Outcome variables
SARA is our primary outcome, which measures motor performance
in ataxia patients with a total score ranging from 0 to 40. SARA scores
correspond with the visual analog scale (VAS score: 0–100) in a linear
fashion and higher SARA scores reflect poor motor performance.19
We also collected age at disease onset as another outcome to test if
vascular risk factors would trigger earlier disease onset.
Statistical analysis
Participants with repeated outcome measures were entered into
analyses. SCA1, 2, 3, and 6 were treated as four independent cohorts
and analyzed separately. We employed repeated measures linear
regression (an exchangeable working within-subject correlation model
via a generalized estimating equation [GEE]) to compute average rates
of disease progression in each SCA group and to assess the associations
between either CHA2DS2-VASc scores or modified CHA2DS2-VASc
scores after controlling for age, sex, and pathological CAG repeat
number. The longitudinal effects of vascular risk factors on disease
progression during the 2-year observation period were assessed by
entering the interaction terms (CHA2DS2-VASc scores 6 time or
modified CHA2DS2-VASc scores 6 time) into the GEE models.
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Coefficients of the interaction terms reflected the direction and
magnitude of how vascular risk factors modified the disease course in
SCAs. In a different linear regression model, we treated age of disease
onset as the outcome and assessed whether CHA2DS2-VASc scores
were associated with earlier onset of ataxia.
All statistical analyses and graphics were performed in the software
R (version 2.11.1). All tests of statistical significance were conducted at
the two-tailed a-level of 0.05.
Results
A total of 319 patients in the CRC-SCA cohort were followed up
with repeated measures of SARA scores, and the mean CHA2DS2-
VASc score was 0.9. The baseline demographics and functional states
of SCA1, 2, 3, 6 were tabulated (Table 1). We found that nearly 60%
of all SCA participants had low cerebrovascular risk factors with
CHA2DS2-VASc50, and 31% scored 2 or greater (range 0–9; 1,
8.8%; 2, 19.4%; 3, 8.2%; 4, 2.5%; 5, 0.3%; 6, 0.3%). The SCA6 group
was older at enrollment and with higher baseline vascular risk factors
than SCA1, 2, and 3. The mean SARA score (0–40) at baseline was
15.1, and the SARA scores captured the progression of ataxia at a rate
of 0.92 point/year.
Higher baseline CHA2DS2-VASc scores were associated with higher
levels of ataxia severity in SCA3 and 6 in univariate models but the
associations disappeared after adjusting for age. CHA2DS2-VASc
scores did not modify the rates of progression of SARA scores in all
SCA participants either. The progression of SARA scores was mostly
determined by age, time, and CAG repeat number. These findings
were not altered after accounting for hyperlipidemia (Table 2). In
addition, disease onset was significantly associated with CAG repeat
numbers and enrollment age but not associated with CHA2DS2-VASc
scores (Table 2).
Discussion
In the present study, vascular risk factors indexed by CHA2DS2-
VASc scores were not associated with age at disease onset or clinical
progression in patients with SCAs. We did not find evidence in the
Table 1. Clinical Features of 319 Participants in the Clinical Research Consortium-Spinocerebellar Ataxia at Enrollment
SCA 1 SCA 2 SCA 3 SCA 6
Demographic feature
Sample size, n 53 69 129 68
Mean age, years (SD) 50.3 (13.0) 50.9 (13.5) 51.4 (12.3) 65.5 (10.8)
Sex, M:F 24:29 29:40 62:67 30:38
White race, % 90.6 73.9 54.2 91.2
Mean age of onset (SD) 40.2 (11.7) 36.4 (11.9) 38.9 (11.9) 52.3 (10.4)
N568 N5127
Mean disease duration (SD) 8.8 (6.9) 13.6 (8.3) 11.5 (7.8) 11.7 (10.5)
N568 N5128
Median repeats (range) 46 (37–59) 39 (23–49) 71 (60–79) 22 (22–27)
N552 N564 N5119 N565
Functional state
SARA score (SD) 14.4 (8.2) 17.1 (7.4) 15.1 (8.9) 14.1 (7.4)
N5128
Vascular risk factors
CHA2DS2-VASc scores (SD) 0.4 (0.9) 0.7 (1.1) 0.7 (1.1) 1.6 (1.5)
[0: 77%] [0: 67%] [0: 63%] [0: 37%]
Modified CHA2DS2-VASc scores (SD) 0.5 (1.1) 0.8 (1.2) 0.8 (1.1) 1.8 (1.6)
[0: 73%] [0: 64%] [0: 61%] [0: 34%]
Abbreviations: CHA2DS2-VASc, Clinical Predictive Score Based on Congestive Heart Failure, Hypertension, Age >75, Diabetes, Prior Stroke, Vascular Disease, Age
65–74, Sex Category; SARA, Scale for Assessment and Rating of Ataxia; SCA, Spinocerebellar Ataxia; SD, Standard Deviation.
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Table 2. Effects of Vascular Risk Factors on Ataxia Progression and Onset in Regression Models
Regression Coefficient in GEE Models (outcome:
SARA score)
Regression Coefficient in Linear Regression Models (outcome:
age at onset)
SCA 1 SCA 2 SCA 3 SCA 6 SCA1 SCA2 SCA3 SCA6
CHA2DS2-VASc model
Age, years 0.22 0.27* 0.51* 0.37* 0.76* 0.60* 0.61* 0.62*
Female 4.65* 21.89 0.08 0.12 21.84 20.85 20.22 20.64
CAG repeat 0.36 1.05* 1.26* 2.26* 20.07 20.99* 20.71* 23.08*
CHA2DS2-VASc scores 22.06 0.28 20.12 20.02 0.75 20.84 0.07 22.08
Time, minutes 0.14* 0.10* 0.07* 0.03
CHA2DS2-VASc 6 time 20.04 20.04 20.02 0.02
Modified CHA2DS2-VASc
model
Age, years 0.23 0.27* 0.51* 0.41* 0.76* 0.64* 0.61* 0.57*
Female 4.63 21.90 0.10 20.05 21.78 21.14 20.20 20.29
CAG repeat 0.41 1.04* 1.26* 2.18* 20.09 21.02* 20.71* 23.03*
Modified CHA2DS2-VASc 21.38 0.28 20.08 20.39 0.45 21.59 0.16 21.54
Time, minutes 0.14* 0.11* 0.07* 0.03
Modified CHA2DS2-VASc 6
time
20.02 20.04 20.02 0.02
Abbreviations: CHA2DS2-VASc, Clinical Predictive Score Based on Congestive Heart Failure, Hypertension, Age >75, Diabetes, Prior Stroke, Vascular Disease, Age 65–74, Sex Category; GEE,

























































CRC-SCA cohort to support the notion that vascular risk factors
would contribute to neurodegeneration in SCAs.
Our study has several strengths. First, this is one of the largest SCA
cohorts diagnosed and evaluated by ataxia experts, allowing us to
examine common vascular risks in rare diseases both at the population
level and with high clinical certainty. Second, the role of vascular risk
factors in neurodegeneration has not been well studied in monogenic
CAG repeat-related ataxias before. Our findings filled the gap for
research focusing on neurovascular integrity and neurodegeneration.
The study limitations mainly came from measurement error. First,
CHA2DS2-VASc scores may not reflect cerebrovascular conditions
well. The score is originally designed for patients with atrial fibrillation
to predict their future stroke risks. Based on the available information,
we could not develop Framingham Cardiovascular Risk Scores or
directly measure the load of cerebrovascular lesions by brain imaging.
Vascular risk data should be systematically collected to better study
their roles in neurodegenerative diseases. Second, most of these
patients are relatively young, except for SCA6 subjects, and do not
have vascular comorbidity, which limited our power to detect the effect
of vascular risk factors. Third, although SARA scores measure clinical
severity of ataxia well, we do not have any pathological evidence or
biomarkers to track progression in SCAs. Future studies may search
for more evidence of vascular pathology in the cerebellum for patients
with SCAs to determine the likelihood of vascular contributions.
In conclusion, disease onset and progression in SCA 1, 2, 3, and 6
are mainly determined by CAG repeats and are likely independent of
common vascular risk factors. Vascular contributions to neurodegen-
eration found within the context of cerebral ischemia or amyloid
deposition in dementia may not apply to SCAs.
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